Crinetics Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 8, 2024


Crinetics Pharmaceuticals announced that it will report second quarter 2024 financial results on Thursday, August 8, 2024, after the close of the U.S. financial markets.

Crinetics Announces July 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)


Crinetics granted non-qualified stock option awards to purchase an aggregate of 137,900 shares of its common stock to eighteen new non-executive employees.

EY Announces Scott Struthers, Ph.D., CEO and Founder of Crinetics Pharmaceuticals, as an Entrepreneur Of The Year® 2024 Pacific Southwest Award Winner


Ernst & Young LLP announces that Scott Struthers, Ph.D., founder and chief executive officer of Crinetics, was named an Entrepreneur Of The Year® 2024 Pacific Southwest Award winner.

Crinetics Announces June 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)


Crinetics granted non-qualified stock option awards to purchase an aggregate of 158,000 shares of its common stock to nine new non-executive employees.

Crinetics Announces Positive Initial Findings at ENDO 2024 for Atumelnant in Two Ongoing, Open-Label Studies for the Treatment of Congenital Adrenal Hyperplasia (CAH) and ACTH-Dependent Cushing’s Syndrome (ADCS)


Crinetics announced initial findings from the development program of its second clinical product candidate, atumelnant, a novel, once-daily oral adrenocorticotropic hormone (ACTH) receptor antagonist.